Premium
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia
Author(s) -
Melo Daniel Fernandes,
de Mattos Barreto Taynara,
Plata Glaura Tinoco,
Araujo Leonardo Rotolo,
Tortelly Violeta Duarte
Publication year - 2020
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12983
Subject(s) - finasteride , medicine , minoxidil , dermatology , hair loss , hair growth , male pattern baldness , clinical trial , physiology , scalp , prostate , cancer
Androgenetic alopecia (AGA) is the most common type of alopecia. Currently, only topical minoxidil and oral finasteride, for men, are approved for its treatment. We report a case of a patient with male pattern AGA treated with topical minoxidil and oral finasteride for 2 years, with partial improvement. At this point, we added mesotherapy to the previous treatment. The patient had 20 sessions of sterile mesotherapy blend, containing minoxidil, finasteride, biotin, and D‐panthenol. We did the injections every two weeks and made the response assessment with global clinical photographs at the 10th and the 20th sessions when we noted a significant visible improvement in hair density and thickness. Mesotherapy or intradermotherapy is defined as a technique that involves the use of multiple intradermal injections of a mixture of compounds in low doses, at many points, near/over the affected sites. In our case, the patient had an excellent response to intradermotherapy as an adjunctive treatment, with no side effects. Although we still need additional clinical trials to standardize the therapy and treatment guidelines, mesotherapy seems to be a therapeutic option in the treatment of AGA, especially if the procedure happens in a medical facility, with correct indication and adequate execution of this promising technique.